Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter November 14, 2017

Drug-drug interactions in cancer chemotherapy: an observational study in a tertiary health care centre

  • Harminder Singh EMAIL logo and Baltej Singh

Abstract

Background:

The objective of this study was to evaluate the occurrence of drug-drug interactions (DDIs) in patients on cancer chemotherapy, with the identification of risk factors for these DDIs.

Methods:

This was a cross-sectional, descriptive study carried out at the Department of Onco-Radiation at Guru Gobind Singh Medical College, Faridkot, Punjab. The DDIs were recorded with the help of a drug interaction/interplay information software.

Results:

In total, 354 interactions were identified from 283 patient records. The mean age of the patients in the study was 49.05±14.35 years. According to the mechanism of interaction, 306 (86.44%) drug interactions were classified as pharmacokinetic and 48 (13.56%) as pharmacodynamic in nature.

Conclusions:

Sensitization of the treating oncologist and the establishment of alerts, such as electronic alerts or a novel fully digital computerized technology that gives a warning when a health expert enters a patient’s prescription orders into the electronic medical documentation, can be helpful in controlling DDIs.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer 2006;6:546–58.10.1038/nrc1887Search in Google Scholar PubMed

2. Richelmann RP, Del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol 2009;20:1907–12.10.1093/annonc/mdp369Search in Google Scholar PubMed

3. Kohler GI, Bode-Boger SM, Busse R, Hoopmann M, Welte T, Boger RH. Drug-drug interactions in medical patients: effects of in hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000;38:504–13.10.5414/CPP38504Search in Google Scholar PubMed

4. Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 2001;14:447–50.10.1016/S0735-6757(96)90147-3Search in Google Scholar

5. Prescott LF. Pharmacokinetic drug interactions. Lancet 1969;294:1239–43.10.1016/S0140-6736(69)90766-1Search in Google Scholar

6. Wolters Kluwer Health. Drug Interaction Facts. Version 4.0. 2006. Available at: http://www.factsandcomparisons.com. Accessed 28 Nov 2015. (Lexi-Interact™, Hudson, Ohio: LexiComp Inc.; April 29, 2012).Search in Google Scholar

7. Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm 2004;61:380–85.10.1093/ajhp/61.4.380Search in Google Scholar PubMed

8. Dirin MM, Mousavi S, Afshari AR, Tabrizian K, Ashrafi MH. Potential drug-drug interactions in prescriptions dispensed in community and hospital pharmacies in east of Iran. J Res Pharm Pract 2014;3:104–7.10.4103/2279-042X.141118Search in Google Scholar PubMed PubMed Central

9. Geneva: World Health Organization. World Health Organization. Technical Report Series No. 498. International drug monitoring: the role of national centers. 1972. Available at: www.who-umc.org/graphics/9277.pdf. Accessed: 30 June 2016.Search in Google Scholar

10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45.10.1038/clpt.1981.154Search in Google Scholar PubMed

11. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49:22–9.10.1093/ajhp/49.9.2229Search in Google Scholar

12. Bjerrum L, Andersen M, Petersen G, Kragstrup J. Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 2003;21:153–8.10.1080/02813430310001806Search in Google Scholar PubMed

13. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007;99:592–80.10.1093/jnci/djk130Search in Google Scholar PubMed

14. Scientific Advisory Board of the Arizona Center for Education and Research on Therapeutics. QT drug lists. Available at: http://www.arizonacert.org. Accessed 16 February 2016.Search in Google Scholar

15. Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquaviva PC. Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients. J Rheumatol 1993;20:263–67.Search in Google Scholar PubMed

16. Johnson EJ, MacGowana AP, Potterb MN, Stockley RJ, White LO, Slade RR. Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy. J Antimicrob Chemother 1990;25:837–42.10.1093/jac/25.5.837Search in Google Scholar PubMed

17. Orr LE. Potentiation of myelosuppression from cancer chemotherapy and thiazidediuretics. Drug Intell Clin Pharm 1981;15:967–70.10.1177/106002808101501209Search in Google Scholar PubMed

18. Tracy TS, Jones DR, Hall SD, Brater DC, Bradley JD, Krohn K. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992;42:121–25.10.1007/BF00278469Search in Google Scholar PubMed

19. Mainwaring P, Grygiel JJ. Interaction of 5-fluorouracil with folates. Aust N Z J Med 1995;25:60.10.1111/j.1445-5994.1995.tb00586.xSearch in Google Scholar PubMed

20. Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther 2007;32:169–75.10.1111/j.1365-2710.2007.00815.xSearch in Google Scholar PubMed

21. Givens CB, Bullock LN, Franks AS. Safety of concomitant tamoxifen and warfarin. Ann Pharmacother 2009;43:1867–71.10.1345/aph.1M176Search in Google Scholar PubMed

22. van Leeuwen RW, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol 2011;22:2334–41.10.1093/annonc/mdq761Search in Google Scholar PubMed

23. Leveque D, Delpeuch A, Gourieux B. New anticancer agents: role of clinical pharmacy services. Anticancer Res 2014;34:1573–78.Search in Google Scholar PubMed

24. Andersson ML, Bottiger Y, Lindh JD, Wettermark B, Eiermann B. Impact of the drug-drug interaction database sfinx on prevalence of potentially serious drug-drug interactions in primary health care. Eur J Clin Pharmacol 2012;69:565–71.10.1007/s00228-012-1338-ySearch in Google Scholar PubMed

Received: 2017-1-6
Accepted: 2017-9-4
Published Online: 2017-11-14
Published in Print: 2017-12-20

©2017 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 8.2.2023 from https://www.degruyter.com/document/doi/10.1515/dmpt-2017-0002/html
Scroll Up Arrow